A new approach to support specialist prescribing of bDMARDs
Arthritis Australia is part of an eight-member Consortium led by NPS MedicineWise, which is the successful recipient of the ‘Value in Prescribing biological disease-modifying anti-rheumatic drugs (bDMARDs)’ government grant.
The grant will fund a project to improve the use of bDMARDs to ensure the best health and economic outcomes from investment in these therapies.
NPS MedicineWise media release – bDMARDS September 2019 (002)
Discover more...
-
New Report Uncovers Alarming Lack of Research Funding into Our Leading Cause of Disability and Pain
New report recommends Medical Research Future Fund (MRFF) mission for arthritis and musculoskeletal diseases A new Research Australia report released today by Arthritis Australia confirms...
-
Building the Case for a National Arthritis & Musculoskeletal Research Mission
On March 30 we launched our new report, Evaluation of Preferred Investment Models for Arthritis and Musculoskeletal Research, making a powerful case for a dedicated...
-
Arthritis Australia appoints Chief Executive Officer
MEDIA RELEASE – FOR IMMEDIATE RELEASE3 February 2026 Arthritis Australia today announced the appointment of Louise Hardy as Chief Executive Officer, following her tenure as...
Sign up to Arthritis Insights
Regular updates, news and research findings delivered to your inbox:
